Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants

NCT01562951 is registered in ClinicalTrials.gov with Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa as lead sponsor.

NCT NCT01562951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01562951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
Lead sponsor
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2012
Completion date
March 31, 2014
Enrollment
15 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, mucosal inflammation